Intellia and the

Recently Intellia Therapeutics in collaboration with Regeneron announced some promising results for their phase I trial using their lead product NTLA-2001, for an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis. In this video I discuss the science behind in vivo CRISPR gene editing and what this means more generally for the CRISPR field or as Intellia phrase it the #NewEraOfMedicine.

TIMESTAMPS
Intro - 00:00
Intellia & CRISPR-Cas9 genome editing - 00:35
NTLA-2001 - 02:30
#NewEraOfMedicine? - 08:00

REFERENCES
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis DOI: 10.1056/NEJMoa2107454 https://www.nejm.org/doi/full/10.1056...

Check out ‪@LifespanNews‬ to see their latest videos!

Icons in intro; "https://www.freepik.com/free-photos-v..."Background vector created by freepik - www.freepik.com